A Phase 1 Randomized, Placebo-controlled, Crossover Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Pharmacokinetics (PK) of ASP8062 in plasma: maximum concentration (Cmax)
研究概览
简要总结
The purpose of this study is to assess the potential for pharmacokinetic (PK) and pharmacodynamics (PD) interactions between ASP8062 and alcohol.
This study will also assess safety and tolerability of a single dose of ASP8062 with or without alcohol.
详细描述
Participants will be admitted to the clinical unit on day -1 of each period and will be residential for 6 days/5 nights. Participants will be discharged from the clinical unit on day 5 of each period on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit. Participants will return to the clinical unit on days 7 and 10 for pharmacokinetic blood sampling.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male and female subjects (21 to 55 years of age, inclusive) who currently consume alcohol regularly but do not meet the diagnostic and statistical manual of mental disorders (DSM-5) criteria for alcohol use disorders and are able to consume 3 to 4 standard drinks at 1 occasion without causing excessive intoxication.
- •Subject currently consumes alcohol regularly but does not meet the diagnostic and statistical manual of mental disorders (DSM-5) criteria for alcohol use disorders and subject is able to consume 3 to 4 standard drinks at 1 occasion without causing excessive intoxication. (note: standard drink =1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor).
- •Subject has a body mass index (BMI) range of 18.5 to 32.0 kg/m2, inclusive and weighs at least 50 kg at screening.
- •Female subject is not pregnant and at least 1 of the following conditions apply:
- •Not a woman of childbearing potential (WOCBP)
- •WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 28 days after final investigational product (IP) administration.
- •Female subject must agree not to breastfeed starting at screening and throughout the study period and for 28 days after final IP administration.
- •Female subject must not donate ova starting at first dose of IP and throughout the study period and for 28 days after final IP administration.
- •Male subject with female partner(s) of childbearing potential (including breastfeeding partner[s]) must agree to use contraception, throughout the treatment period and for 90 days after final IP administration.
- •Male subject must not donate sperm during the treatment period and for 90 days after final IP administration.
- •Male subject with a pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 90 days after final IP administration.
- •Subject agrees to not participate in another interventional study while participating in the present study.
排除标准
- •Subject has received investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
- •Subject has any condition which makes the subject unsuitable for study participation.
- •Female subject who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening.
- •Subject has a known or suspected hypersensitivity to ASP8062, alcohol or any components of the formulations used.
- •Subject has had previous exposure with ASP
- •Subject has any of the liver function tests (alkaline phosphatase [ALP], alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase and total bilirubin [TBL]) above 1.5 × upper limit of normal (ULN) on day -1 of period
- •In such a case, the assessment may be repeated once.
- •Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to first IP administration.
- •Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
- •Subject has a current, untreated moderate or severe mental illness as assessed by the Mini International Neuropsychiatric Interview (MINI).
- •Subject has a relevant history of suicide attempt or suicidal behavior. Any recent suicidal ideation within the last 12 months or subject who is at significant risk to commit suicide using the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening and on day -1 of period
- •Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 1 week prior to day -
- •Subject has any clinically significant abnormality following the investigator's review of the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on day -
- •Subject has a mean pulse < 45 or > 90 bpm; mean systolic blood pressure (SBP) > 140 mmHg; mean diastolic blood pressure (DBP) > 90 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least 5 minutes; pulse will be measured automatically) on day -
- •If the mean blood pressure exceeds the limits above, 1 additional triplicate may be taken.
- •Subject has a mean QT interval using Fridericia's correction formula (QTcF) of > 430 msec (for male subjects) and > 450 msec (for female subjects) on day -
- •If the mean QTcF exceeds the limits above, 1 additional triplicate ECG may be taken.
- •Subject has used any prescribed or nonprescribed drugs (including vitamins and natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to first IP administration, except for occasional use of paracetamol (up to 2 g/day), topical dermatological products, including corticosteroid products, hormonal contraceptives and hormone replacement therapy (HRT).
- •Subject has smoked, used tobacco-containing products and nicotine or nicotine-containing products (e.g., electronic vapes) within 6 months prior to screening or the subject tests positive for cotinine at screening.
- •Subject has a history of alcoholism or drug/chemical/substance abuse within 2 years prior to screening or the subject tests positive for alcohol at screening or on day -1 of period
- •Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within 3 months prior to day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) at screening or on day -1 of period
- •Subject has used any inducer of metabolism (e.g., barbiturates and rifampin) in the 3 months prior to day -
- •Subject has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within 7 days prior to day -1 and/or received a transfusion of any blood or blood products within 60 days.
- •Subject has a positive serology test for hepatitis A virus antibodies (immunoglobulin M), hepatitis B core antibodies, hepatitis B surface antigen, hepatitis C virus antibodies or antibodies to human immunodeficiency virus type 1 and/or type 2 at screening.
- •Subject is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.
研究组 & 干预措施
Sequence 1: Participants receiving treatment sequence A,B,C,D
Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol
干预措施: ASP8062 (Drug)
Sequence 1: Participants receiving treatment sequence A,B,C,D
Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol
干预措施: Alcohol (Drug)
Sequence 1: Participants receiving treatment sequence A,B,C,D
Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol
干预措施: ASP8062 Placebo (Drug)
Sequence 3: Participants receiving treatment sequence C,A,D,B
Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol
干预措施: Alcohol (Drug)
Sequence 1: Participants receiving treatment sequence A,B,C,D
Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol
干预措施: Alcohol Placebo (Drug)
Sequence 2: Participants receiving treatment sequence B,D,A,C
Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol
干预措施: ASP8062 (Drug)
Sequence 2: Participants receiving treatment sequence B,D,A,C
Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol
干预措施: Alcohol (Drug)
Sequence 2: Participants receiving treatment sequence B,D,A,C
Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol
干预措施: ASP8062 Placebo (Drug)
Sequence 2: Participants receiving treatment sequence B,D,A,C
Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol
干预措施: Alcohol Placebo (Drug)
Sequence 3: Participants receiving treatment sequence C,A,D,B
Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol
干预措施: ASP8062 (Drug)
Sequence 3: Participants receiving treatment sequence C,A,D,B
Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol
干预措施: ASP8062 Placebo (Drug)
Sequence 3: Participants receiving treatment sequence C,A,D,B
Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol
干预措施: Alcohol Placebo (Drug)
Sequence 4: Participants receiving treatment sequence D,C,B,A
Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol
干预措施: ASP8062 (Drug)
Sequence 4: Participants receiving treatment sequence D,C,B,A
Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol
干预措施: Alcohol (Drug)
Sequence 4: Participants receiving treatment sequence D,C,B,A
Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol
干预措施: ASP8062 Placebo (Drug)
Sequence 4: Participants receiving treatment sequence D,C,B,A
Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol
干预措施: Alcohol Placebo (Drug)
结局指标
主要结局
Pharmacokinetics (PK) of ASP8062 in plasma: maximum concentration (Cmax)
时间窗: Up to Day 10 of each treatment period
Cmax will be recorded from the pharmacokinetic (PK) plasma samples collected.
Change from baseline in reaction times defined by Cogstate battery: psychomotor function
时间窗: Baseline and Day 1 of each treatment period (90 minutes, 2.5 hours, 4 hours and 6 hours post dose)
The psychomotor function domain will be assessed using the Detection Test. Participants will tap a moving target on a grid and reaction times will be recorded. Change from baseline will be reported at indicated time points. Lower scores mean better performance.
Pharmacokinetics (PK) of ASP8062 in plasma: area under the concentration time curve from the time of dosing extrapolated to time infinity (AUCinf)
时间窗: Up to Day 10 of each treatment period
AUCinf will be recorded from the pharmacokinetic (PK) plasma samples collected.
Pharmacokinetics (PK) of alcohol in Ethanol plasma: Cmax
时间窗: Day 1 of each treatment period
Cmax will be recorded from the pharmacokinetic (PK) plasma samples collected.
Change from baseline in reaction times defined by Cogstate battery: attention
时间窗: Baseline and Day 1 of each treatment period (90 minutes, 2.5 hours, 4 hours and 6 hours post dose)
The attention domain will be assessed using the Identification Test. Participants will answer "yes" or "no" to the question "is the card red or not?" and reaction times will be recorded. Change from baseline will be reported at indicated time points. Lower scores mean better performance.
Pharmacokinetics (PK) of alcohol in Ethanol plasma: AUClast
时间窗: Day 1 of each treatment period
AUClast will be recorded from the pharmacokinetic (PK) plasma samples collected.
Change from baseline in reaction times defined by Cogstate battery: working memory
时间窗: Baseline and Day 1 of each treatment period (90 minutes, 2.5 hours, 4 hours and 6 hours post dose)
The working memory domain will be assessed using the One Back Test. Participants will answer "yes" or "no" to the question "is the previous card the same?" and reaction times will be recorded. Change from baseline will be reported at indicated time points. Lower scores mean better performance.
Postural stability test assessed via the single-leg stance test
时间窗: Day 1 of each treatment period
Limb dominance will be determined and recorded prior to performing the single leg stance test. Time will commence when eyes are closed and end for any of the following reasons: participant uses arms; participant uses the raised foot; participant moves the weight bearing foot to maintain balance; a maximum of 45 seconds has elapsed; or participant opens eyes. The test will be repeated 3 times and each time will be recorded. The best and the average of the 3 trials will also be recorded.
Change from baseline in number of error attempts defined by Cogstate battery: executive function
时间窗: Baseline and Day 1 of each treatment period (90 minutes, 2.5 hours, 4 hours and 6 hours post dose)
The executive function domain will be assessed using the Groton Maze Learning Test. Participants will be asked to find a hidden pathway and the total number of errors made while attempting to learn the same pathway will be recorded. Change from baseline will be reported at indicated time points. Lower scores mean better performance.
次要结局
- Number of participants with laboratory value abnormalities and/or adverse events (AEs)(Up to 55 Days (End of Study))
- Number of participants with vital sign abnormalities and /or adverse events (AEs)(Up to 55 Days (End of Study))
- Number of participants with suicidal ideation and/or behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)(Day 1 of each treatment period)
- Number of participants with Blood oxygen saturation (SpO2) level abnormalities and/or Adverse Events (AEs)(Day 1 of each treatment period)
- Safety and tolerability assessed by nature, frequency, and severity of Adverse Events (AEs)(Up to 55 Days (End of Study))
- Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)(Up to 55 Days (End of Study))